Recipharm sees H1 sales bump; Valeant pours $142M into plant; Aurobindo hits FDA issues;

> Swedish CDMO Recipharm said its sales were up 46% in H1 to about €185 million ($203 million). Report

> Valeant ($VRX) spent $142 million in the second quarter on restructuring work at a Bausch + Lomb plant in Waterford, Ireland. Release

> Aurobindo plant in India received an FDA Form 483. Report

> Federal officials have extracted a guilty plea and $450,000 in penalties from U.S.-based Aracoma Drug Company, a pharmacy that sold drugs over the Internet that had not been legally prescribed. Report

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.